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Fever in neutropenia (FN) is the most frequent potentially life threatening complication of chemotherapy
for cancer. Prediction of the risk to develop complications, integrated into clinical decision rules, would
allow for risk-stratiﬁed treatment of FN. This retrospective, single center cohort study in pediatric patients
diagnosed with cancer before 17 years, covered two decades, 1993 to 2012. In total, 703 FN episodes in
291 patients with chemotherapy (maximum per patient, 9) were reported here. Twenty-nine characteristics
of FN were collected: 6 were patient- and cancer-related, 8 were characteristics of history, 8 of clinical
examination, and 7 laboratory results in peripheral blood, all known at FN diagnosis. In total 28 FN
outcomes were assessed: 8 described treatment of FN, 6 described microbiologically deﬁned infections
(MDI), 4 clinically deﬁned infections, 4 were additional clinical composite outcomes, and 6 outcomes were
related to discharge. These data can mainly be used to study FN characteristics and their association with
outcomes over time and between centers, and for derivation and external validation of clinical
decision rules.
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Background & Summary
Fever in neutropenia (FN) is the most common potentially lethal complication of chemotherapy for
cancer1,2. About half of the children treated with chemotherapy for cancer develop at least one FN
episode3,4. In the 1970s up to 30% of children with FN died1,5. The introduction of routine emergency
hospitalization and empirical administration of intravenous broad-spectrum antibiotics reduced
mortality to around 1%2,6.
However, a bacterial infection is detected in a minority of children with FN. This implies
overtreatment in the majority of children with FN7,8. Such overtreatment has important negative
implications on both societal and individual level. These include costs both due to antibiotics and to
hospitalization9, promotion of bacterial resistance, risk of nosocomial infections, and ﬁnally reduced
quality of life of patients and their families during hospitalization10.
These observations led to the development and wide application of clinical decision rules (CDRs)
predicting the risk of relevant complications in adults with FN11. The implementation of CDRs, and
correspondingly of risk adapted treatment of FN, is actually recommended as well in pediatric oncology,
but only rarely used in practice12,13. Currently, there is no consensus on which of the many published
CDRs should be used for FN in pediatric oncology because the methodological quality of most CDRs is not
optimal14, and none of these rules has been found to perform sufﬁciently well when externally
validated15–17 with only one exception8 described very recently18. Differences in the populations studied19,
in local management of FN and deﬁnitions of outcome criteria20, or missing clinical information in
different datasets hamper even individual patient data meta-analysis21,22. Changes of clinical characteristics
over time, and even of their associations with outcomes, may explain a further part of the insufﬁcient
predictive performance of these CDRs when validated externally.
This study aimed to collect long-term data on 29 predeﬁned characteristics in pediatric patients at
diagnosis of FN potentially associated with two main FN outcomes, bacteremia and severe bacterial
infection (SBI). Of these characteristics 6 were patient- and cancer-related, 8 were characteristics of
history, 8 of clinical examination, and 7 laboratory results in peripheral blood, all known at FN diagnosis.
A total of 28 FN outcomes were assessed: 8 described treatment of FN, 6 described microbiologically
deﬁned infections (MDI), 4 clinically deﬁned infections, 4 were additional clinical composite outcomes,
and 6 outcomes were related to discharge.
The clinical motivation of this study was to generate data for the development and external validation
of CDRs in pediatric FN, ﬁnally leading to evidence-based risk-stratiﬁed empirical treatment of FN in
these patients.
This study was designed as a retrospective, single center cohort study in pediatric patients diagnosed
with cancer before 17 years at the Division of Pediatric Hematology/Oncology, Department of Pediatrics,
Inselspital, Bern University Hospital, University of Bern, Switzerland, covering two decades, 1993 to 2012.
This hospital provides tertiary care for a population of roughly one million inhabitants. The Division of
Pediatric Hematology/Oncology unit has an inpatient unit with 8 beds, plus a large outpatient unit. It
treats around 40 newly diagnosed pediatric patients with all kind of malignancies per year. Besides, it
performs myeloablative chemotherapy followed by autologous stem cell transplantation for the majority
of Switzerland, covering around 6 million inhabitants.
All clinical information was directly extracted from patient charts.
From 1993 to 2012, 800 patients had been diagnosed with cancer up to the age of 17 years in Bern. Of
these, 596 (75%) had received chemotherapy. Charts were not accessible in 13 (2%). In the remaining 583
(98% of 596) patients, 846 FN episodes had been clinically diagnosed. FN criteria were not ascertainable
in 43 (5%) and not fulﬁlled in 91 (11%) of these episodes, and relevant non-resolvable inconsistencies led
to the exclusion of 9 (1%) episodes. The remaining 703 (83%) FN episodes were studied here. (Fig. 1).
In the 291 (50%) of the 583 patients with at least one FN episode included in this study, the median
number of episodes of FN per patient was 2 (maximum, 9). The distribution of gender, age at diagnosis
and of diagnostic groups did not change signiﬁcantly over time regarding both patients and episodes of
FN. Bacteremia was detected in 148 (21%), and SBI in 357 (51%) of the 703 FN episodes.
Simultaneously collected data on the risk to develop FN during chemotherapy from the 583 patients
with cancer and accessible charts, have been published in Scientiﬁc Data before23.
These data can mainly be used (1) to study FN characteristics over time and between centers; (2) to
study the association of FN characteristics with outcomes over time and between centers; (3) to derive
corresponding CDRs for risk-adapted treatment of FN in pediatric patients; and (4) to externally validate
CDRs derived from other datasets.
Methods
Study design
A retrospective, single site cohort study covering two decades, from 1993 to 2012, was performed at the
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, Bern University
Hospital, University of Bern, Switzerland. All information was retrospectively extracted from patients
charts as described23,24.
This study was approved by the Institutional Review Board (Direktion Lehre und Forschung,
Inselspital Bern; registration number, 13-06-11; last update, April 02, 2014), including waiver of informed
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consent. On June 30, 2014, data were fully anonymized before analysis, in order to comply with the
requests of the new Swiss Federal Law on Human Research.
Corresponding data on the risk to develop FN during chemotherapy have been published
elsewhere23,25.
Patients
All children and adolescents diagnosed with cancer (including Langerhans cell histiocytosis and all
tumors of the central nervous system) and treated with chemotherapy were eligible. Patients were
primarily identiﬁed via the Swiss Childhood Cancer Registry (SCCR)26. In order to reduce recruitment
bias, clinically used patient lists and databases of previously published studies4,8,24,27,28, were searched.
This resulted in 3 additional patients not listed in the SCCR database (Fig. 1). Extensive plausibility
checks performed by an experienced pediatric oncologist (RAA) detected relevant inconsistencies in 10
FN episodes. Because data were fully anonymized, these inconsistencies could be resolved in only one
episode, while the 9 remaining episodes were deleted from the database (Fig. 1).
Age at cancer diagnosis was restricted to ≤17 years. Multiple FN episodes per patients were allowed.
Information on clinical characteristics and FN episodes including outcomes was extracted directly from
patient charts.
Treatment of cancer
Most patients were treated according to established international protocols. Clinical management
regarding prophylaxis and treatment of FN essentially remained unchanged during the entire study
period. Patients did not receive any antibiotic prophylaxis beyond prophylaxis against Pneumocystis
jirovecii pneumonia with oral trimethoprim/sulfamethoxazole, which was replaced by inhaled
pentamidine in selected patients24. Daily subcutaneous granulocyte colony-stimulating factor (G-CSF)
was applied if requested by protocol24.
Fever in neutropenia, deﬁnition and treatment
An FN episode was deﬁned as fever in a patient with severe chemotherapy-induced neutropenia. Until
July 8, 2007, fever was deﬁned as an axillary temperature ≥38.5 °C persisting ≥2 h, or a single
temperature ≥39.0 °C. Since July 9, 2007, fever was deﬁned as single tympanic temperature ≥39.0 °C27.
In the setting of rising temperatures, the different limits used for the different measurement methods
have been shown to be comparable29. Severe neutropenia was deﬁned as an absolute neutrophil count
(ANC) o0.5 G/L30. FN episodes additionally diagnosed for clinical reasons at lower temperatures and/or
Patients and FN Episodes 
Reported from Swiss Childhood Cancer Registry (n=797) 
Additional patients from institutional lists (n=3) 
Patients with cancer (n=800) 
Patients excluded (n=217) 
- No chemotherapy received (n=204) 
- Charts not accessible (n=13) 
Patients studied (n=583) FN episodes reported (n=846) 
FN episodes excluded (n=143) 
- FN criteria not ascertainable (n=43) 
- FN criteria not fulfilled (n=91) 
- Relevant inconsistencies not resolvable (n=9) 
FN episodes studied (n=703) 
in 291 patients 
Figure 1. Flowsheet of patients and FN episodes.
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with an ANC ≥ 0.5 G/L31 were excluded and not studied here (Fig. 1). Bacteremia was deﬁned as any
bacteria detected in blood culture from the beginning until the end of the FN episode.
The beginning of an FN episode was deﬁned as the time point when the FN criteria were fulﬁlled. The
end of this episode was deﬁned as the time point when antibiotics were stopped, the patient was
discharged, or chemotherapy was restarted, whichever occurred earlier. If the FN criteria were fulﬁlled
again after this time point, this counted as a further FN episode. Correspondingly, multiple FN episodes
per observation period were possible. Taken together with the stopping criteria mentioned above, FN
episodes could thus end despite continued neutropenia, and second FN episodes could be diagnosed
within one episode of neutropenia23. Recovery from neutropenia was assumed when the ANC was rising,
there was no speciﬁc absolute ANC level deﬁning recovery.
Routine management for patients with FN included emergency hospitalization and empirical broad-
spectrum intravenous antimicrobial therapy, usually once daily ceftriaxone plus amikacin32. In the
absence of documented infection, intravenous antibiotics were continued until resolution of fever for ≥
48 hours and increasing leukocyte count or ANC. First-day step-down to oral outpatient treatment was
performed only in the second decade studied in FN episodes with low risk of complications; ﬁrst, in the
experimental arm of a prospective interventional study from 2004 to 200710, and thereafter within clinical
routine from 2010 onwards8,33.
Characteristics studied
A total of 29 characteristics available at FN diagnosis were recorded. First, there were 6 patient- and
cancer-related characteristics: Number of FN episode counted from the beginning of the study, sex, age
group at cancer diagnosis (0 to 3.99 years, 4 to 7.99 years, 8 to 11.99 years, and 12 to 16.99 years),
diagnostic group of cancer, ﬁrst versus later cancer, non-relapsed versus relapsed cancer.
Second, there were 8 characteristics related to patient history known at FN diagnosis: Time period of
FN diagnosis, age group at FN diagnosis, bone marrow involvement (≥5% leukemic cells, or any
malignant cells in solid tumors, determined at the start of the last parenteral chemotherapy preceding the
speciﬁc FN episode), intensity of chemotherapy (Table 1), prophylaxis with G-CSF or GM-CSF, central
venous access device, hospitalization before FN diagnosis, and potential triggers for fever (transfusion,
cytarabine).
Third, there were 8 characteristics related to ﬁndings on clinical examination at FN diagnosis: highest
temperature reported or measured, general health condition, chills, oral mucositis, comorbidities
requiring hospitalization independently from fever, clinical signs of bacterial infection, clinical signs of
viral infection, and details regarding clinical signs of infection, if applicable.
Finally, there were 7 laboratory characteristics, all determined in peripheral blood at FN diagnosis:
hemoglobin, leukocyte count, ANC, absolute monocyte count, absolute phagocyte count, thrombocyte
count, and C-reactive protein (CRP).
Outcomes studied
In total, 28 outcomes were recorded. First, 8 outcomes described treatment of FN: Choice of empirical
antibiotics32, switching of intravenous antibiotics for any reason (step down from intravenous to oral did
not count as switching), duration of intravenous antibiotics, duration of oral antibiotics, duration of
intravenous antifungal therapy, intensive care unit (ICU) treatment for diagnostics or for organ support34,
duration of ICU treatment, and duration of hospitalization for FN.
Second, 6 outcomes described microbiologically infections (MDI): Bacteremia, deﬁned as any
bacteria detected in blood culture before recovery from severe neutropenia (irrespective of the bacterial
species8), bacterial species detected in blood, microbiologically deﬁned bacterial infection other than
bacteremia (irrespective of localization of infection or detection method), microbiologically deﬁned
fungal infection (irrespective of localization of infection or detection method), microbiologically deﬁned
viral infection (irrespective of localization of infection or detection method), and MDI of any kind35.
Third, 4 outcomes described clinically deﬁned infections: Radiologically conﬁrmed pneumonia,
potentially life-threatening complication (PLTC) of infection as judged by the treating physician8, death
from infection during neutropenia (outside palliative situations)20, and details describing the infection.
Level Intensity Expected duration of severe neutropenia
1 Minimally myelosuppressive None expected
2 Brieﬂy myelosuppressive ≤10 days
3 Strongly myelosuppressive >10 days
4 Myeloablative Hematopoietic stem cell recovery required
Table 1. Myelosuppressive intensity of chemotherapy. Modiﬁed from refs24 and28, plus ref.31 regarding
the distinction of level 2 versus 3.
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Fourth, in order to facilitate analysis, 4 additional clinical composite outcomes were deﬁned: A serious
medical complication (SMC) was deﬁned as death from infection, ICU treatment, or PLTC8; an adverse
event (AE) was deﬁned as MDI, SMC, or radiologically conﬁrmed pneumonia8; a severe bacterial
infection (SBI) was deﬁned as death from infection, positive bacterial culture of normally sterile body
ﬂuids (including bacteremia), radiologically conﬁrmed pneumonia, clinically unequivocal diagnosis of a
bacterial infection as judged by the treating physician or serum CRP>150mg/L at FN diagnosis8; and
unexplained fever was deﬁned as FN without clinical or microbiological evidence of infection35.
Finally, 6 discharge-related outcomes were deﬁned: Discharge with versus without antibiotics
(prophylactic antibiotics not included), absolute leukocyte, neutrophil, monocyte and phagocyte counts at
discharge, and rehospitalization because of fever or complications within 7 days from discharge.
Considering the set of 12 FN core outcomes recently proposed in a consensus statement of an
international panel of FN experts20, 3 outcomes (MDI, unexplained fever and infection related mortality)
can be assessed with these data without modiﬁcation. Three further outcomes (bacteremia, transfer to
ICU and SMC) can be assessed with modiﬁcations, while the 6 remaining outcomes of the proposed set
(clinically documented infection, sepsis, severe sepsis, septic shock, all cause 30-days mortality, and
relapse of primary infection) are not assessable here because of missing information.
Data classiﬁcation
In order not to compromise the irreversibility of anonymization, periods of 4 years were used for age
groups both at cancer diagnosis and at FN diagnosis (4 periods: 0 to 3.99 years, 4 to 7.99 years, 8 to 11.99
years, and 12 to 16.99 years), and for time periods of FN diagnosis (5 periods: 1993 to 1996, 1997 to 2000,
2001 to 2004, 2005 to 2008, and 2009 to 2012).
Chemotherapy was classiﬁed into 4 levels of myelosuppressive intensity according to the expected
duration of severe neutropenia as described24,28, which is an extension of an earlier model using only 2
levels36 (Table 1)23. This classiﬁcation does not cover the additional risk of infection due to new
therapeutic agents like rituximab that do not lead to relevant neutropenia.
Code availability
This study did not use any computer codes to generate the dataset. Microsoft Excel was used to enter,
store and quality check the collected data.
Data Records
A single data record resulted from this study. It contains information of characteristics and outcomes on
the 703 FN episodes periods studied in these 291 patients (File 17C.Characteristics_FN_Episodes.csv.
Data Citation 1) (Table 2).
Information on patients at time of study entry can be extracted from this ﬁle by selecting the ﬁrst FN
episode per patient (EPI.PER.PAT = 1).
Detailed information on variable speciﬁcation is included in a readme ﬁle (File 17C.Character-
istics_FN_Episodes.ReadMe.csv. Data Citation 1).
Technical Validation
Data was retrieved from patients charts into a paper case report form (File 17C_CRF.pdf. Data Citation 1)
by different persons, i.e., co-investigators, medical students, and research assistants, all instructed by the
senior author (RAA). The information of these CRF’s was then entered into a spreadsheet, without double-
checking.
Reduction of recruitment bias
Patients were primarily identiﬁed via the Swiss Childhood Cancer Registry26. In order to reduce
recruitment bias, information on patients was complemented by clinically used institutional patients
lists for the entire period, and patient lists from earlier research projects for a part of the period covered
here4,8,24,27,28 (Fig. 1).
Increasing reliability of information on FN episodes
A simple restricted deﬁnition of FN episodes, based on veriﬁable quantitative information both on fever
and on neutropenia was used as described23. Correspondingly, FN episodes additionally diagnosed
Observations Time covered Center Data source Data
Patients 1993 to 2012a Berna Swiss Childhood Cancer Registry26 Institutional
patient lists
17C.Characteristics_FN_Episodes.csv [EPI.
PER.PAT = 1]
FN Episodes 1993 to 2012a Berna Chart records 17C.Characteristics_FN_Episodes.csv
Table 2. Overview. aIdentical for both patients and FN Episodes.
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clinically when fever and or neutropenia limits had not been reached31, or when these limits were not
ascertainable, were excluded.
A simple deﬁnition of bacteremia was used as well, without the need of partly subjective judgment if
detection of a common commensal in a blood culture should be considered as infection, i.e., bacteremia,
or as contamination.
In case of inconsistencies or unclear information found in the charts, the person retrieving data from
charts called the senior author, an experienced pediatric haematologist-oncologist (RAA), to consult
patient charts again and to resolve these questions. In the majority of relevant inconsistencies detected in
the database only after irreversible anonymization, however, these could not be resolved any more, which
led to the exclusion of the respective FN episode (Fig. 1).
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